Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma

被引：23
|
作者：
Young, Kate [1 ]
Smyth, Elizabeth [1 ]
Chau, Ian [1 ]
机构：
[1] Royal Marsden Hosp, Gastrointestinal Oncol Unit, Sutton SM2 5PT, Surrey, England
来源：
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2015年 / 8卷 / 06期
关键词：
angiogenesis; gastric cancer; gastro-oesophageal cancer; ramucirumab; vascular endothelial growth factor; vascular endothelial growth factor receptor 2; RANDOMIZED PHASE-III; 2ND-LINE CHEMOTHERAPY; 1ST-LINE THERAPY; SUPPORTIVE CARE; DOUBLE-BLIND; OPEN-LABEL; GROWTH; COMBINATION; PLUS; VEGF;
D O I：
10.1177/1756283X15592586
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.
引用
收藏
页码：373 / 383
页数：11
相关论文
共 50 条
  • [31] A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer
    Sahin, Ugur
    Schuler, Martin
    Richly, Heike
    Bauer, Stefan
    Krilova, Anna
    Dechow, Tobias
    Jerling, Markus
    Utsch, Magdalena
    Rohde, Christoph
    Dhaene, Karl
    Huber, Christoph
    Tuereci, Ozlem
    EUROPEAN JOURNAL OF CANCER, 2018, 100 : 17 - 26
  • [32] Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer
    Smyth, Elizabeth
    Thuss-Patience, Peter C.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (05) : 272 - 280
  • [33] Ramucirumab: targeting angiogenesis in the treatment of gastric cancer
    Smyth, Elizabeth C.
    Tarazona, Noelia
    Chau, Ian
    IMMUNOTHERAPY, 2014, 6 (11) : 1177 - 1186
  • [34] First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial
    Quintero Aldana, G.
    Salgado, M.
    Candamio, S.
    Mendez, J. C.
    Jorge, M.
    Reboredo, M.
    Vazquez Tunas, L.
    Romero, C.
    Covela, M.
    Fernandez Montes, A.
    Carmona, M.
    Vidal Insua, Y.
    Lopez, R.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (04) : 495 - 502
  • [35] First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial
    G. Quintero Aldana
    M. Salgado
    S. Candamio
    J. C. Méndez
    M. Jorge
    M. Reboredo
    L. Vázquez Tuñas
    C. Romero
    M. Covela
    A. Fernández Montes
    M. Carmona
    Y. Vidal Insua
    R. López
    Clinical and Translational Oncology, 2020, 22 : 495 - 502
  • [36] Improving individualised therapies in localised gastro-oesophageal adenocarcinoma
    Svrcek, Magali
    Voron, Thibault
    Andre, Thierry
    Smyth, Elizabeth C.
    de la Fouchardiere, Christelle
    LANCET ONCOLOGY, 2024, 25 (09) : e452 - e463
  • [37] Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
    Jing, Chao
    Bai, Zhigang
    Zhang, Jun
    Jiang, Hongpeng
    Yang, Xiaobao
    Yan, Shu
    Yin, Jie
    Cai, Jun
    Zhang, Zhongtao
    Deng, Wei
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (05) : 2035 - 2044
  • [38] Lymphangiogenesis and Prognostic Significance of Vascular Endothelial Growth Factor C in Gastro-oesophageal Junction Adenocarcinoma
    Xie, Liang-Xi
    Zhai, Tian-Tian
    Yang, Li-Ping
    Yang, Eleanor
    Zhang, Xiao-Hui
    Chen, Jiong-Yu
    Zhang, Hao
    INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2013, 94 (01) : 39 - 46
  • [39] Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer
    Korkeila, E. A.
    Salminen, T.
    Kallio, R.
    Mikkola, M.
    Auvinen, P.
    Pyrhonen, S.
    Ristamaki, R.
    SUPPORTIVE CARE IN CANCER, 2017, 25 (09) : 2771 - 2777
  • [40] Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) -: gastrointestinal cancer group
    Van Cutsem, Eric
    Van de Velde, Cornelius
    Roth, Arnaud
    Lordick, Florian
    Koehne, Claus-Henning
    Cascinu, Stefano
    Aapro, Matti
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (02) : 182 - 194
12345